RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Francis Eko to Bacterial Vaccines

This is a "connection" page, showing publications Francis Eko has written about Bacterial Vaccines.
Connection Strength

6.305
  1. Tanner T, Medhavi FNU, Richardson S, Omosun YO, Eko FO. In silico design and analysis of a multiepitope vaccine against Chlamydia. Pathog Dis. 2024 Feb 07; 82.
    View in: PubMed
    Score: 0.862
  2. Richardson S, Medhavi F, Tanner T, Lundy S, Omosun Y, Igietseme JU, Carroll D, Eko FO. Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine. Front Immunol. 2021; 12:698737.
    View in: PubMed
    Score: 0.719
  3. Howard S, Richardson S, Benyeogor I, Omosun Y, Dye K, Medhavi F, Lundy S, Adebayo O, Igietseme JU, Eko FO. Differential miRNA Profiles Correlate With Disparate Immunity Outcomes Associated With Vaccine Immunization and Chlamydial Infection. Front Immunol. 2021; 12:625318.
    View in: PubMed
    Score: 0.703
  4. Pais R, Omosun Y, Igietseme JU, Fujihashi K, Eko FO. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses. Front Immunol. 2019; 10:1577.
    View in: PubMed
    Score: 0.627
  5. Pais R, Omosun Y, He Q, Blas-Machado U, Black C, Igietseme JU, Fujihashi K, Eko FO. Rectal administration of a chlamydial subunit vaccine protects against genital infection and upper reproductive tract pathology in mice. PLoS One. 2017; 12(6):e0178537.
    View in: PubMed
    Score: 0.543
  6. Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine. 2011 May 12; 29(21):3802-10.
    View in: PubMed
    Score: 0.353
  7. Eko FO, Ekong E, He Q, Black CM, Igietseme JU. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine. 2011 Feb 04; 29(7):1472-80.
    View in: PubMed
    Score: 0.347
  8. Eko FO, Talin BA, Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum Vaccin. 2008 May-Jun; 4(3):176-83.
    View in: PubMed
    Score: 0.332
  9. Ekong EE, Okenu DN, Mania-Pramanik J, He Q, Igietseme JU, Ananaba GA, Lyn D, Black C, Eko FO. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol Med Microbiol. 2009 Mar; 55(2):280-91.
    View in: PubMed
    Score: 0.300
  10. Ifere GO, He Q, Igietseme JU, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Eko FO. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect. 2007 Jun; 40(3):188-200.
    View in: PubMed
    Score: 0.271
  11. Macmillan L, Ifere GO, He Q, Igietseme JU, Kellar KL, Okenu DM, Eko FO. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol. 2007 Feb; 49(1):46-55.
    View in: PubMed
    Score: 0.261
  12. Richardson S, Bell CR, Medhavi F, Tanner T, Lundy S, Omosun Y, Igietseme JU, Eko FO. A novel cold-chain free VCG-based subunit vaccine protects against Chlamydia abortus-induced neonatal mortality in a pregnant mouse model. Front Immunol. 2023; 14:1243743.
    View in: PubMed
    Score: 0.211
  13. Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA, Lyn D, Black CM, Igietseme JU. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine. 2003 Apr 02; 21(15):1694-703.
    View in: PubMed
    Score: 0.203
  14. Zuo Z, Zou Y, Li Q, Guo Y, Zhang T, Wu J, He C, Eko FO. Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge. Sci Rep. 2021 05 17; 11(1):10389.
    View in: PubMed
    Score: 0.178
  15. Igietseme JU, Eko FO, Black CM. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines. 2011 Nov; 10(11):1585-96.
    View in: PubMed
    Score: 0.092
  16. He Q, Martinez-Sobrido L, Eko FO, Palese P, Garcia-Sastre A, Lyn D, Okenu D, Bandea C, Ananaba GA, Black CM, Igietseme JU. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology. 2007 Sep; 122(1):28-37.
    View in: PubMed
    Score: 0.067
  17. Igietseme J, Eko F, He Q, Bandea C, Lubitz W, Garcia-Sastre A, Black C. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv. 2005 May; 2(3):549-62.
    View in: PubMed
    Score: 0.059
  18. Igietseme JU, Eko FO, He Q, Bandea C, Black CM. Developing effective delivery systems for Chlamydia vaccines. Curr Opin Mol Ther. 2004 Apr; 6(2):182-94.
    View in: PubMed
    Score: 0.054
  19. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines. 2004 Feb; 3(1):23-34.
    View in: PubMed
    Score: 0.054
  20. Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines. 2003 Feb; 2(1):129-46.
    View in: PubMed
    Score: 0.050
  21. Igietseme JU, Eko FO, He Q, Black CM. Combination vaccines: design strategies and future trends. Expert Rev Vaccines. 2006 Dec; 5(6):739-45.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support